EQT completes sale of shares in Galderma Group AG

EQT VIII has completed the sale of 19 million shares in Galderma Group AG, generating total gross proceeds of approximately CHF 1.86 billion.
EQT completes sale of shares in Galderma Group AG
  • The sale resulted in aggregate gross proceeds of c. CHF 1.86 billion, of which EQT received c. CHF 494 million

Further to previous announcements, an affiliate of the funds known as EQT VIII (“EQT”) is pleased to announce the completion of the placement of 19,031,811 shares in Galderma Group AG (SIX: GALD) (the “Company”) (the “Shares”) for aggregate gross proceeds of c. CHF 1.86 billion via an accelerated bookbuilding process (the “Placement”).  

As part of the Placement, EQT received gross proceeds of c. CHF 494 million. The Placement was completed on 2 June 2025. Goldman Sachs, Jefferies, Morgan Stanley, RBC and UBS acted as joint global coordinators and joint bookrunners for the Placement.

Contact

EQT Press Office, press@eqtpartners.com

About EQT

EQT is a purpose-driven global investment organization with EUR 273 billion in total assets under management (EUR 142 billion in fee-generating assets under management) as of 31 March 2025, within two business segments – Private Capital and Real Assets. EQT owns portfolio companies and assets in Europe, Asia Pacific and the Americas and supports them in achieving sustainable growth, operational excellence and market leadership.

More info: www.eqtgroup.com
Follow EQT on LinkedIn, X, YouTube and Instagram

About Galderma Group AG

Galderma Group AG is a pure-play leader in the dermatology category, with a presence in approximately 90 countries. It delivers an innovative, science-based portfolio of premium flagship brands and services that cover the full spectrum of the rapidly growing dermatology market. This includes Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. Since its foundation in 1981, Galderma has dedicated its focus and passion to the human body's largest organ – the skin – addressing individual consumer and patient needs with superior outcomes in collaboration with healthcare professionals. 
LikeDiscussion
Share

Discussion

You are commenting on EQT completes sale of shares in Galderma Group AG

You must be logged in to add a comment

There are no comments

Be the first to add to the discussion

EQT Group
EQT Group
Stockholm, Sweden
EQT is a purpose-driven global investment organisation with nearly three decades of consistent investment performance across multiple geographies, sectors, and strategies
buyoutprivate equityinfrastructurereal estategrowthprivate debtvc

Related news

EQT X hits the hard cap, raising EUR 22 billion (USD 24 billion) in total commitments

EQT X hits the hard cap, raising EUR 22 billion (USD 24 billion) in total commitments

In what is EQT’s largest ever fundraise, its flagship private equity fund raises EUR 22 billion (USD 24 billion) in total commitments, of which EUR 21.7 (USD 23.5 billion) are fee-generating assets under management, exceeding the EUR 20 billion (USD 21.6 billion) target · This represents a near 40 percent increase on EQT IX, thanks to strong support from existing and new investors, with a greater share of commitments coming from private wealth · EQT X builds on EQT Private Equity’s 30-year track record of strong performance, investing predominantly in the Healthcare, Technology and Tech-enabled Services sectors in Europe and North America.

EQT Group